• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用流式细胞术荧光原位杂交(FACS-FISH)可提高浆细胞 FISH 的检测率。

Superior detection rate of plasma cell FISH using FACS-FISH.

机构信息

Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic, Rochester, MN, US.

Department of Medicine, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, US.

出版信息

Am J Clin Pathol. 2024 Jan 4;161(1):60-70. doi: 10.1093/ajcp/aqad108.

DOI:10.1093/ajcp/aqad108
PMID:37658775
Abstract

OBJECTIVES

Fluorescence in situ hybridization (FISH) for plasma cell neoplasms (PCNs) requires plasma cell (PC) identification or purification strategies to optimize results. We compared the efficacy of cytoplasmic immunoglobulin FISH (cIg-FISH) and fluorescence-activated cell sorting FISH (FACS-FISH) in a clinical laboratory setting.

METHODS

The FISH analysis results of 14,855 samples from individuals with a suspected PCN subjected to cytogenetic evaluation between 2019 and 2022 with cIg-FISH (n = 6917) or FACS-FISH (n = 7938) testing were analyzed.

RESULTS

Fluorescence-activated cell sorting-FISH increased the detection rate of abnormalities in comparison with cIg-FISH, with abnormal results documented in 54% vs 50% of cases, respectively (P < .001). It improved the detection of IGH::CCND1 (P < .001), IGH::MAF (P < .001), IGH::MAFB (P < .001), other IGH rearrangements (P < .001), and gains/amplifications of 1q (P < .001), whereas the detection rates of IGH::FGFR3 fusions (P = .3), loss of 17p (P = .3), and other abnormalities, including hyperdiploidy (P = .5), were similar. Insufficient PC yield for FISH analysis was decreased between cIg-FISH and FACS-FISH (22% and 3% respectively, P < .001). Flow cytometry allowed establishment of ploidy status in 91% of cases. In addition, FACS-FISH decreased analysis times, workload efforts, and operating costs.

CONCLUSIONS

Fluorescence-activated cell sorting-FISH is an efficient PC purification strategy that affords significant improvement in diagnostic yield and decreases workflow requirements in comparison with cIg-FISH.

摘要

目的

荧光原位杂交(FISH)检测浆细胞肿瘤(PCN)需要浆细胞(PC)的鉴定或纯化策略来优化结果。我们比较了细胞质免疫球蛋白 FISH(cIg-FISH)和荧光激活细胞分选 FISH(FACS-FISH)在临床实验室环境中的效果。

方法

分析了 2019 年至 2022 年间进行细胞遗传学评估的疑似浆细胞肿瘤患者的 14855 例样本的 FISH 分析结果,这些患者分别接受了 cIg-FISH(n=6917)或 FACS-FISH(n=7938)检测。

结果

与 cIg-FISH 相比,FACS-FISH 提高了异常的检出率,异常结果分别记录在 54%和 50%的病例中(P<0.001)。它提高了IGH::CCND1(P<0.001)、IGH::MAF(P<0.001)、IGH::MAFB(P<0.001)、其他 IGH 重排(P<0.001)和 1q 获得/扩增(P<0.001)的检出率,而IGH::FGFR3 融合(P=0.3)、17p 缺失(P=0.3)和其他异常,包括超二倍体(P=0.5)的检出率相似。cIg-FISH 和 FACS-FISH 之间用于 FISH 分析的 PC 产量不足分别减少了 22%和 3%(P<0.001)。流式细胞术可确定 91%病例的倍性状态。此外,FACS-FISH 减少了分析时间、工作量和运营成本。

结论

与 cIg-FISH 相比,FACS-FISH 是一种有效的 PC 纯化策略,可显著提高诊断产量,并降低工作流程要求。

相似文献

1
Superior detection rate of plasma cell FISH using FACS-FISH.使用流式细胞术荧光原位杂交(FACS-FISH)可提高浆细胞 FISH 的检测率。
Am J Clin Pathol. 2024 Jan 4;161(1):60-70. doi: 10.1093/ajcp/aqad108.
2
Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH.浆细胞肿瘤的风险分层:浆细胞特异性细胞质免疫球蛋白荧光原位杂交(cIg FISH)与常规 FISH 的比较。
Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):366-74. doi: 10.1016/j.clml.2012.05.003. Epub 2012 Jun 1.
3
[Cytoplasmic light-chain immunofluorescence combined with FISH in bone marrow smears to detect cytogenetic abnormalities in multiple myeloma].[骨髓涂片细胞质轻链免疫荧光联合荧光原位杂交检测多发性骨髓瘤细胞遗传学异常]
Zhonghua Xue Ye Xue Za Zhi. 2024 Jun 14;45(6):566-570. doi: 10.3760/cma.j.cn121090-20231204-00291.
4
Cytogenetic testing by fluorescence in situ hybridization is improved by plasma cell sorting in multiple myeloma.荧光原位杂交的细胞遗传学检测通过多发性骨髓瘤中的浆细胞分选得到改善。
Sci Rep. 2022 May 18;12(1):8287. doi: 10.1038/s41598-022-11676-w.
5
Modified cIg-FISH protocol for multiple myeloma in routine cytogenetic laboratory practice.常规细胞遗传学实验室实践中用于多发性骨髓瘤的改良cIg-FISH方案。
Cancer Genet. 2014 Jan-Feb;207(1-2):31-4. doi: 10.1016/j.cancergen.2013.12.001. Epub 2013 Dec 27.
6
Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.采用间期荧光原位杂交技术研究多发性骨髓瘤患者的分子细胞遗传学畸变。
Exp Oncol. 2007 Jun;29(2):116-20.
7
[Application of CD138 Immunomagnetic Sorting Myeloma Cells Combined with Fluorescence in Situ Hybridization for Detecting Cytogenetic Abnormalities of Multiple Myeloma].CD138免疫磁珠分选骨髓瘤细胞联合荧光原位杂交技术在检测多发性骨髓瘤细胞遗传学异常中的应用
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Jun;25(3):807-812. doi: 10.7534/j.issn.1009-2137.2017.03.031.
8
[Application of CD138 Immunomagnetic Bead Sorting Combined with Fluorescence in Situ Hybridization in Multiple Myeloma].CD138免疫磁珠分选联合荧光原位杂交在多发性骨髓瘤中的应用
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Oct;30(5):1496-1500. doi: 10.19746/j.cnki.issn.1009-2137.2022.05.029.
9
[Detection of the Cytogenetic Aberrations in Multiple Myeloma by Using Microrray Comparative Genomic Hybridization].[应用微阵列比较基因组杂交技术检测多发性骨髓瘤的细胞遗传学异常]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018 Oct;26(5):1389-1395. doi: 10.7534/j.issn.1009-2137.2018.05.022.
10
High-risk cytogenetics in multiple myeloma: Further scrutiny of deletions within the IGH gene region enhances risk stratification.多发性骨髓瘤中的高危细胞遗传学:对 IGH 基因区域内缺失的进一步研究增强了风险分层。
Genes Chromosomes Cancer. 2020 Oct;59(10):569-574. doi: 10.1002/gcc.22874. Epub 2020 Jun 19.

引用本文的文献

1
Temporal genomic dynamics shape clinical trajectory in multiple myeloma.时间基因组动力学塑造多发性骨髓瘤的临床病程。
Nat Genet. 2025 Aug 20. doi: 10.1038/s41588-025-02292-1.
2
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group.多发性骨髓瘤风险分层的细胞遗传学结果检测与报告指南:癌症基因组学联盟浆细胞肿瘤工作组报告
Blood Cancer J. 2025 Jun 18;15(1):86. doi: 10.1038/s41408-025-01286-w.
3
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes.
基于维奈托克的治疗组合用于复发/难治性多发性骨髓瘤:实践模式及继发性细胞遗传学异常对结局的影响
Blood Cancer J. 2025 Apr 4;15(1):57. doi: 10.1038/s41408-025-01264-2.